Healthcare Industry News: Biliary Stent
News Release - November 15, 2007
Medtronic Receives FDA Marketing Clearance For Complete SE Biliary Stent SystemSANTA ROSA, Calif.--(HSMN NewsFeed)--Medtronic, Inc. (NYSE:MDT ), announced today that it has received 510(k) marketing clearance from the U.S. Food and Drug Administration for the Complete SE (self-expanding) Biliary Stent System, which is indicated for use in the palliative treatment of malignant neoplasms in the biliary tree – cancerous tumors in the bile duct that can compromise digestion by restricting the flow of digestive fluids.
Bench testing has shown the Complete SE Biliary Stent System to be extremely accurate in terms of stent placement. Accurate stent placement can decrease the likelihood that additional stents are necessary to cover the entire narrowing of the bile duct.
The safety and effectiveness of this device in the vascular system have not been established.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMedtronic receives CE Mark approval for Affera(TM) Mapping and Ablation System to treat atrial arrhythmias
Medtronic Receives CE Mark for Extravascular Defibrillator System That Treats Abnormal Heart Rhythms
Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in U.S.